Compare BWMX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMX | GYRE |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 621.6M | 625.6M |
| IPO Year | 2019 | 2004 |
| Metric | BWMX | GYRE |
|---|---|---|
| Price | $17.19 | $4.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $29.20 | $18.67 |
| AVG Volume (30 Days) | 59.4K | ★ 133.8K |
| Earning Date | 10-22-2026 | 11-17-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $25.39 | N/A |
| Revenue Next Year | $14.43 | $27.49 |
| P/E Ratio | $12.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.41 | $4.27 |
| 52 Week High | $19.79 | $9.14 |
| Indicator | BWMX | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 29.97 |
| Support Level | $15.62 | N/A |
| Resistance Level | $19.22 | $7.44 |
| Average True Range (ATR) | 0.55 | 0.50 |
| MACD | 0.13 | -0.18 |
| Stochastic Oscillator | 86.40 | 6.17 |
Betterware de Mexico SAPI de CV is a company in the consumer product goods industry focused on home organization and beauty and personal care products, commercialized through person-to-person selling. The Group operates through two segments: Home organization under the Betterware brand, including kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, bedroom and wellness. Products are sold through catalogues and distributed through distributors and associates. The Beauty and personal care (B&PC) segment under the JAFRA brand, which generates maximum revenue, includes fragrance, color, skin care and toiletries, distributed through leaders and consultants. The Group operates in Mexico, which generates maximum revenue, the United States and Latam.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.